Thiazolidinediones News and Research

RSS
Thiazolidinediones are adjunctive therapies for diabetes mellitus (type 2) and related diseases.
NCoR deficiency may pump up muscles and prevent diabetes

NCoR deficiency may pump up muscles and prevent diabetes

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

Researchers create powerful anti-diabetic prototype drugs with lesser side effects

Researchers create powerful anti-diabetic prototype drugs with lesser side effects

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

New biological insights into fat tissue

New biological insights into fat tissue

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

TZDs might serve as new agents for addiction treatment

TZDs might serve as new agents for addiction treatment

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

ChemoCentryx presents CCX140 clinical data at EASD

ChemoCentryx presents CCX140 clinical data at EASD

Use of oral medications for diabetes increases among Americans: Report

Use of oral medications for diabetes increases among Americans: Report

Two diabetes medications increase risk of heart attack, failure: Study

Two diabetes medications increase risk of heart attack, failure: Study

Postmenopausal women with diabetes taking TZDs at increased fracture risk

Postmenopausal women with diabetes taking TZDs at increased fracture risk

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients